A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

NCT05695950 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatomyositis

Interventions

DRUG: GLPG3667
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV